Ann: Sales Update, page-32

let's say they hit $15 million in revenue with 40-45% ebitda margin.
management will be hesitant to give any guidance for 2024 because they have 0 visibility into future demand.
besides a favorable fda decision there is no catalyst until august 2024. that will be a binary outcome.

I am worried about all the build up inventory to keep margins in the IS high. cash flow will look miserable again. hopefully they explain the the annual report why they keep increasing inventory and why investors should not be worried about this trend.